Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...

COPENHAGEN, Denmark, May 9, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...

The earnings before interest, tax, depreciation and amortization margin rose to 31% from 3%, and Bavarian Nordic maintained guidance for a full-year EBITDA margin of 26%-30% with revenue still seen at ...

Recommendations for the use of chikungunya vaccine were recently discussed at a meeting of the Advisory Committee on Immunization Practices.

Bavarian Nordic A/S (($BVNRY)) has held its Q1 earnings call. Read on for the main highlights of the call. Bavarian Nordic’s recent earnings call ...

Bavarian Nordic A/S ( ($BVNRY) ) has released its Q1 earnings. Here is a breakdown of the information Bavarian Nordic A/S presented to its ...

Welcome to the Bavarian Nordic Q1 2025 Results ... In addition to the strong financial performance, we've also launched Chikungunya vaccine where it's been approved in the U.S., Europe and ...